GlassScriptPhysician profile
Chante D Mckim
NPI 1679246417
$1,691.86
in general payments reported to CMS, 2019-2025
35 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.64 · 2022: $467 · 2023: $399 · 2024: $378 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $223.66 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $148.68 | 2022-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $146.73 | 2022-2024 | |
| Abbvie INC. | $138.56 | 2022-2024 | |
| Dexcom, INC. | $110.79 | 2022-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $107.52 | 2022-2025 | Verquvo, Gardasil 9, Capvaxive |
| Novo Nordisk INC | $92.06 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $76.38 | 2022-2025 | Breztri |
| Abbott Laboratories | $59.34 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $43.46 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.14 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $36.56 | 2025 | Voquezna |
| Radius Health, INC. | $35.79 | 2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $35.03 | 2022-2023 | Eliquis |
| Collegium Pharmaceutical, INC. | $31.18 | 2025 | Jornay Pm |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $29.51 | 2024 | Ibsrela |
| Verona Pharma, INC. | $28.58 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.96 | 2022 | |
| Viatris Specialty LLC | $22.15 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $21.26 | 2023 | Gvoke Hypopen |
| Medtronic, INC. | $20.49 | 2025 | Minimed 780g |
| Resmed Corp | $19.73 | 2025 | |
| Corium, LLC | $18.63 | 2023 | Azstarys |
| Tandem Diabetes Care, INC. | $17.67 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alkermes, INC. | $16.71 | 2023 | Aristada, Lybalvi |
| Nevro Corp. | $16.57 | 2023 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $16.51 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.00 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $15.62 | 2025 | Arexvy, Bexsero, Shingrix |
| Organon LLC | $15.22 | 2025 | Nexplanon |
| Ironshore Pharmaceuticals INC. | $13.85 | 2024 | |
| Exact Sciences Corporation | $13.29 | 2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $12.27 | 2022 | |
| Sobi, INC | $11.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chante Mckim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.